MUSCULAR DYSTROPHY ASSOCIATION, INC. for MUSCULAR DYSTROPHY ASSOCIATION, INC.
What was lobbied
9 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Advocated for passage of measures that would provide financial assistance to nonprofits providing essential healthcare services to the neuromuscular disease community throughout the COVID-19 pandemic.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRITTANY JOHNSON HERNANDEZ | — |
| PAUL MELMEYER | — |
Medicare/Medicaid MMM
Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Cited opposition to the expansion of Section 1115 demonstration waivers that would create substantial barriers to care for patients and families who enroll in Medicaid.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRITTANY JOHNSON HERNANDEZ | — |
Labor Issues/Antitrust/Workplace LBR
Advocated for passage of the Disability Employment Incentive Act (S.255, HR 3992) to create tax credits to incentivize the hiring and retaining of individuals living with disabilities.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARC GOTTSCHALK New | — |
| BRITTANY JOHNSON HERNANDEZ | — |
Health Issues HCR
Health care issues affecting individuals with neuromuscular disease including therapy development, newborn screening, screening and diagnosis, adequate insurance coverage, and access to care. Advocated for passage of H.R. 4393, the Advancing Access to Precision Medicine Act, provide for a State option under the State Medicaid plan to provide DNA sequencing clinical services for certain children. Advocated for funding for the FDA Orphan Products Grants Program. Advocated for passage of H.R. 3235, the Access to Genetic Counselor Services Act of 2019, to provide for expanded coverage of services provided by genetic counselors. Advocated for the passage of the Newborn Screening Saves Lives Reauthorization Act, H.R. 2507 / S. 2158, to encourage investment in the national newborn screening program in order to detect more neuromuscular conditions early to speed appropriate interventions for patients. Advocated for robust funding of the national newborn screening program. Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions. Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019. Advocated for maintaining strong incentives for rare disease drug development included within the Orphan Drug Act (PL 97-414) Advocated on the Promising Pathway Act (S.3872) and the ACT for ALS Act (H.R.7071). Advocated for access to healthcare via telemedicine/telehealth throughout and after the COVID-19 public health emergency. H.R. 6800, HEROES Act and related COVID-19 packages, support various provisions relevant to people with NMDs including increased federal support for state Medicaid programs; Medicaid maintenance of effort provisions; nationwide reopening of Marketplace special enrollment period; expansion of paid sick leave and paid family and medical leave; making permanent flexibilities to allow Medicare beneficiaries to continue accessing healthcare through telehealth; more resources to enhance testing and contact tracing in underserved communities; opposing waivers from IDEA and the Rehab Act; and better data collection on the impact of COVID-19 on people with disabilities. Continuing to support passage of legislation and proposals to protect patients from surprise medical billing and hold patients harmless.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARC GOTTSCHALK | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| PAUL MELMEYER | — |
Budget/Appropriations BUD
Advocated in favor of robust appropriations funding for the National Institutes of Health, the Food and Drug Administration, the Health Resources and Services Administration, and the Centers for Disease Control and Prevention. Advocated for ongoing and robust funding of the national newborn screening program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARC GOTTSCHALK | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| PAUL MELMEYER | — |
Insurance INS
Advocated for passage of the ALS Disability Insurance Act (HR 1407, S 578) which would eliminate the five month waiting period for individuals with ALS to obtain Social Security disability insurance. Advocated for passage of H.R. 4393, the Advancing Access to Precision Medicine Act, provide for a State option under the State Medicaid plan to provide DNA sequencing clinical services for certain children. Advocated for passage of H.R. 3235, the Access to Genetic Counselor Services Act of 2019, to provide for expanded coverage of services provided by genetic counselors. Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Issues related to surprise medical billing.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARC GOTTSCHALK | — |
| BRITTANY JOHNSON HERNANDEZ | — |
Aviation/Airlines/Airports AVI
Advocated for access to air travel for individuals with neuromuscular conditions by advocating for ongoing implementation of the Air Carrier Access Act (ACAA) and the Federal Aviation Administration Reauthorization Act of 2017. Advocated for passage of the Air Carrier Access Amendments Act (S. 669, H.R. 1549). Advocated for further air travel access improvements for individuals with disabilities through regulation by FAA and DoT.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARC GOTTSCHALK New | — |
| BRITTANY JOHNSON HERNANDEZ | — |
Pharmacy PHA
Advocated for provisions that enable ongoing access to necessary medications and treatments for neuromuscular disease patients throughout the COVID-19 pandemic.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRITTANY JOHNSON HERNANDEZ | — |
| PAUL MELMEYER | — |
Medical/Disease Research/Clinical Labs MED
Advocated in favor of robust appropriations funding for the National Institutes of Health, the Food and Drug Administration, the Health Resources and Services Administration, and the Centers for Disease Control and Prevention.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARC GOTTSCHALK | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| PAUL MELMEYER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.